AZN EV/EBITDA: current value, 10-year range and year-by-year history
Cash & Leverage
AZN's ev/ebitda is lower than 83% of the last 10 years.
EV/EBITDA History
AZN EV/EBITDA by year
Yearly range of AZN’s ev/ebitda from 2016 to 2026. Over the full period it ranged from 8.0 to 35.0, averaging 18.3.
| Year | Low | Average | High | Year-end |
|---|---|---|---|---|
| 2026 | 8.0 | 12.8 | 17.7 | 13.6 |
| 2025 | 14.2 | 15.8 | 17.7 | 15.0 |
| 2024 | 14.4 | 17.4 | 20.5 | 14.7 |
| 2023 | 15.6 | 20.8 | 27.2 | 17.1 |
| 2022 | 22.4 | 29.1 | 35.0 | 27.7 |
| 2021 | 15.5 | 19.9 | 27.7 | 27.0 |
| 2020 | 16.7 | 20.2 | 23.0 | 17.4 |
| 2019 | 14.4 | 17.1 | 21.7 | 21.7 |
| 2018 | 14.2 | 17.1 | 20.1 | 15.5 |
| 2017 | 10.7 | 12.3 | 14.3 | 12.6 |
| 2016 | 13.1 | 14.8 | 16.6 | 14.0 |
Get notified when AZN EV/EBITDA crosses a threshold
Free — one alert setup, notifications by push, Telegram, or Discord.
An acquisition-style valuation multiple: Enterprise Value (market cap + net debt) divided by operating earnings before accounting adjustments. Compares companies fairly regardless of their capital structure.
(Market Cap + Net Debt) / EBITDAUnlike P/E, this metric accounts for debt — two companies with identical operations but different leverage will show similar EV/EBITDA. Low vs history suggests the total business is modestly priced.
- EBITDA ignores capital expenditure. For asset-heavy businesses (airlines, mining, utilities), this understates the real cost — use EV/EBIT or EV/FCF instead.
- Large acquisitions temporarily spike net debt and can distort the ratio for 1–2 years during integration.
Is AZN EV/EBITDA High or Low Right Now?
AstraZeneca PLC's EV/EBITDA is currently 13.6, which is historically cheap relative to its 10-year historical range. The 10-year median EV/EBITDA for AZN is approximately 17.3. See all AZN valuation metrics →
Unlock 10y, 15y, 20y, and 30y history with peer comparison and CSV export.